We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.51B
1-Year Est. Return 546.08%
This Fund
S&P 500
This Quarter Est. Return
-6.3%
1 Year Est. Return
+546.08%
3 Year Est. Return
+2,136.34%
5 Year Est. Return
+8,050.66%
10 Year Est. Return
–
AUM
$885M
AUM Growth
-$32.3M
Cap. Flow
+$73.3M
Cap. Flow %
8.29%
Top 10 Hldgs %
94.27%
Holding
16
New
1
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$123M
2
BCYC
Bicycle Therapeutics
BCYC
+$24.2M
3
COGT icon
Cogent Biosciences
COGT
+$11.4M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$32.3M
2
TYRA icon
Tyra Biosciences
TYRA
+$22.9M
3
GERN icon
Geron
GERN
+$22M
4
TERN
Terns Pharmaceuticals
TERN
+$7.82M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$11.2B
$190M 21.46%
2,360,077
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$146M 16.5%
1,924,626
– –
SYRE icon
3
Spyre Therapeutics
SYRE
$8.17B
$94.5M 10.67%
4,018,101
+3,639,680
+962% +$123M
APGE
4
DELISTED
Apogee Therapeutics
APGE
$80.6M 9.11%
2,048,647
– –
ELVN icon
5
Enliven Therapeutics
ELVN
$3.68B
$74.8M 8.46%
3,202,798
– –
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.66B
$71.5M 8.08%
2,762,837
– –
KNSA icon
7
Kiniksa Pharmaceuticals
KNSA
$6.19B
$59.8M 6.76%
3,204,841
– –
COGT icon
8
Cogent Biosciences
COGT
$5.76B
$52.5M 5.93%
6,225,641
+1,500,000
+32% +$11.4M
ATXS
9
DELISTED
Astria Therapeutics
ATXS
$32.3M 3.65%
3,554,129
– –
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.3B
$32.3M 3.65%
931,890
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.48B
$24M 2.71%
1,845,813
– –
BCYC
12
Bicycle Therapeutics
BCYC
$258M
$21.6M 2.44%
+1,069,199
New +$24.2M
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
$5.1M 0.58%
748,996
-1,291,004
-63% -$7.82M
GERN icon
14
Geron
GERN
$848M
– –
-6,666,667
Closed -$22M
MRUS
15
DELISTED
Merus
MRUS
– –
-717,254
Closed -$32.3M
TYRA icon
16
Tyra Biosciences
TYRA
$1.68B
– –
-1,393,329
Closed -$22.9M

Similar funds

AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.51B AUM 85.85% 1-Year Est. Return
NB
NBT Bank Norwich, New York $1.51B AUM 24.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
SC
Styrax Capital New York $1.52B AUM 57.44% 1-Year Est. Return
RIM
Rush Island Management New York $1.51B AUM 8.12% 1-Year Est. Return
WFA
Wellspring Financial Advisors Cleveland, Ohio $1.52B AUM 29.68% 1-Year Est. Return

Fairmount Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Fairmount Funds Management held 16 positions worth $885M, down 3.5% from $917M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Fairmount Funds Management deployed $73.3M of net new capital in Q2 2024, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Bicycle Therapeutics: 1,069,199 shares worth $21.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $7.82M trimmed.

  • Fairmount Funds Management's largest Q2 2024 buy was Bicycle Therapeutics: 1,069,199 shares worth $21.6M.
  • Fairmount Funds Management added most to Spyre Therapeutics in Q2 2024, an estimated $123M increase.
  • Fairmount Funds Management's biggest Q2 2024 reduction was Terns Pharmaceuticals, cutting an estimated $7.82M.
  • Fairmount Funds Management fully exited Merus in Q2 2024, selling an estimated $32.3M.
  • Fairmount Funds Management's ten largest holdings make up 94% of its $885M portfolio in Q2 2024.
  • Fairmount Funds Management opened 1 new position and closed 3 in Q2 2024.
  • Fairmount Funds Management's portfolio value fell 3.5% quarter-over-quarter to $885M.

Based on Fairmount Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.